(A and B) Tumor growth curve (A) and representative tumor images (B) show tumor progression in anti-NK1.1 and anti-NK1.1 + anti–PD-L1 combination treatment groups (n = 8 tumors for IgG and n = 6 tumors for treated group). A total of 250,000 primary tumor cells per MFP from C3-HET tumors were injected into REAR mice. (C) Percentage of NK cell population (CD45+DX5+) of live cells in primary tumors of indicated groups. (D and E) Tumor growth curve (D) and representative tumor images (E) are shown for the indicated treatment group (n = 10 tumors for vehicle control and n = 8 tumors for treated group). A total of 150,000 primary tumor cells per MFP from BRCA1cKO tumors were injected into C57BL/6 mice. (F and G) Representative tumor images (F) and tumor growth curve (G) are shown for the indicated treatment group (n = 4 tumors for anti–PD-L1 and n = 6 tumors for the rest of the other groups). A total of 100,000 primary tumor cells per MFP from C3-HET mice were injected into REAR mice. Vehicle control and LGK-974 data points are shared with fig. S9F. (H) Flow cytometry analysis shows the NK cell frequency (CD45+DX5+) of live cells in C3-HET tumors. The scatterplots show the number per group of samples used for flow analysis. Statistical significance was determined by two-way ANOVA with Dunnett’s multiple comparisons test in (A), (D), and (F) and by one-way ANOVA with Dunnett’s multiple comparisons test in (C) and (H); *P < 0.05, **P < 0.01, ***P ≤ 0.001, and ****P ≤ 0.0001. The data are presented as means ± SEM. Arrows indicate the start point for drug dose. Anti-IgG (250 μg per mouse), anti-NK1.1 (250 μg per mouse), and anti–PD-L1 (250 μg per mouse) antibodies were given three times per week. An oral dose of LGK-974 (5 mg/kg of body weight) was given every alternate day, and olaparib (50 mg/kg of body weight) was given daily by intraperitoneal injection. ns, not significant.